European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Commission (EC) has approved KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination ...
scanx

Sun Pharma’s UNLOXCYT gets NCCN Category 2A nod for laCSCC

UNLOXCYT receives NCCN Category 2A Preferred Designation for laCSCC patients ineligible for surgery or radiation. The ...

Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer

Approval based on AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment No disease recurrences reported among responders after ...